المؤلفون: Symmans WF; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston., Yau C; Department of Surgery, University of California, San Francisco., Chen YY; Department of Pathology, University of California, San Francisco., Balassanian R; Department of Pathology, University of California, San Francisco., Klein ME; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis., Pusztai L; Department of Medicine, Medical Oncology, Yale University, New Haven, Connecticut., Nanda R; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois., Parker BA; Division of Hematology-Oncology, Department of Medicine, University of California, San Diego, La Jolla., Datnow B; Department of Pathology, University of California, San Diego, La Jolla., Krings G; Department of Pathology, University of California, San Francisco., Wei S; Department of Anatomic Pathology, University of Alabama at Birmingham., Feldman MD; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia., Duan X; Department of Pathology, Loyola University, Chicago, Illinois., Chen B; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota., Sattar H; Department of Pathology, University of Chicago, Chicago, Illinois., Khazai L; Department of Pathology, Moffitt Cancer Center, Tampa, Florida., Zeck JC; Department of Pathology, Georgetown University, Washington, DC., Sams S; Department of Pathology, University of Colorado Anschutz Medical Center, Aurora., Mhawech-Fauceglia P; Department of Pathology, University of Southern California, Los Angeles., Rendi M; Department of Anatomic Pathology, University of Washington, Seattle., Sahoo S; Department of Pathology, University of Texas Southwestern, Dallas., Ocal IT; Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona., Fan F; Department of Pathology, University of Kansas Medical Center, Kansas City., LeBeau LG; Department of Pathology, University of Arizona Health Sciences, Tucson., Vinh T; Department of Pathology, Inova Health System, Fairfax, Virginia., Troxell ML; Department of Pathology, Oregon Health and Science University, Portland., Chien AJ; Division of Hematology-Oncology, Department of Medicine, University of California, San Francisco., Wallace AM; Department of Surgery, University of California, San Diego, La Jolla., Forero-Torres A; Division of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham., Ellis E; Medical Oncology, Swedish Cancer Institute, Seattle, Washington., Albain KS; Division of Hematology-Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois., Murthy RK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Boughey JC; Department of Surgery, Mayo Clinic, Rochester, Minnesota., Liu MC; Department of Oncology, Mayo Clinic, Rochester, Minnesota., Haley BB; Division of Hematology-Oncology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas., Elias AD; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Center, Aurora., Clark AS; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia., Kemmer K; Division of Hematology-Oncology, Department of Medicine, Oregon Health & Science University, Portland., Isaacs C; Division of Hematology-Oncology, Department of Medicine, Georgetown University, Washington, DC., Lang JE; Department of Surgery, University of Southern California, Los Angeles., Han HS; Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida., Edmiston K; Department of Surgery, Inova Schar Cancer Institute, Fairfax, Virginia., Viscusi RK; Department of Surgery, University of Arizona Health Sciences, Tucson, Arizona., Northfelt DW; Department of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona., Khan QJ; Division of Oncology, Department of Medicine, University of Kansas, Kansas City., Leyland-Jones B; Medical Oncology, Avera Cancer Institute, Sioux Falls, South Dakota., Venters SJ; Department of Laboratory Medicine, University of California, San Francisco., Shad S; Department of Surgery, University of California, San Francisco., Matthews JB; Department of Surgery, University of California, San Francisco., Asare SM; Quantum Leap Healthcare Collaborative, San Francisco, California., Buxton M; Berry Consultants, LLC, Houston, Texas., Asare AL; Quantum Leap Healthcare Collaborative, San Francisco, California., Rugo HS; Division of Hematology-Oncology, Department of Medicine, University of California, San Francisco., Schwab RB; Division of Hematology-Oncology, Department of Medicine, University of California, San Diego, La Jolla., Helsten T; Division of Hematology-Oncology, Department of Medicine, University of California, San Diego, La Jolla., Hylton NM; Department of Radiology and Biomedical Imaging, University of California, San Francisco., van 't Veer L; Department of Laboratory Medicine, University of California, San Francisco., Perlmutter J; Gemini Group, Ann Arbor, Michigan., DeMichele AM; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia., Yee D; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis., Berry DA; Berry Consultants, LLC, Houston, Texas., Esserman LJ; Department of Surgery, University of California, San Francisco.

المصدر: JAMA oncology [JAMA Oncol] 2021 Nov 01; Vol. 7 (11), pp. 1654-1663.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology , Neoadjuvant Therapy*/methods, Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Middle Aged ; Neoplasm, Residual ; Prognosis ; Progression-Free Survival ; Receptor, ErbB-2/analysis

المؤلفون: Yee D; Masonic Cancer Center, University of Minnesota, Minneapolis., DeMichele AM; Perelman School of Medicine, University of Pennsylvania, Philadelphia., Yau C; Department of Surgery, University of California, San Francisco., Isaacs C; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Symmans WF; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston., Albain KS; Loyola University Chicago Stritch School of Medicine, Chicago, Illinois., Chen YY; Department of Pathology, University of California, San Francisco., Krings G; Department of Pathology, University of California, San Francisco., Wei S; Department of Pathology, University of Alabama Birmingham., Harada S; Department of Pathology, University of Alabama Birmingham., Datnow B; Department of Pathology, University of California, San Diego., Fadare O; Department of Pathology, University of California, San Diego., Klein M; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis., Pambuccian S; Department of Pathology, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois., Chen B; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota., Adamson K; Department of Pathology, Swedish Cancer Institute, Seattle, Washington., Sams S; Department of Pathology, University of Colorado, Denver., Mhawech-Fauceglia P; Keck School of Medicine, University of Southern California, Los Angeles., Magliocco A; Department of Pathology, Moffitt Cancer Center, Tampa, Florida., Feldman M; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia., Rendi M; Department of Anatomic Pathology, University of Washington, Seattle., Sattar H; Department of Pathology, University of Chicago, Chicago, Illinois., Zeck J; Department of Pathology, Georgetown University, Washington, DC., Ocal IT; Laboratory Medicine and Pathology, Mayo Clinic Scottsdale, Scottsdale, Arizona., Tawfik O; Department of Pathology and Laboratory Medicine, University of Kansas, Lawrence., LeBeau LG; Department of Pathology, University of Arizona, Tucson., Sahoo S; Department of Pathology, University of Texas Southwestern, Dallas., Vinh T; Inova Pathology Institute, Inova Health System, Falls Church, Virginia., Chien AJ; Division of Hematology and Oncology, University of California, San Francisco., Forero-Torres A; Division of Hematology and Oncology, University of Alabama Birmingham., Stringer-Reasor E; Division of Hematology and Oncology, University of Alabama Birmingham., Wallace AM; Department of Surgery, University of California, San Diego., Pusztai L; Medical Oncology, Yale Cancer Center, New Haven, Connecticut., Boughey JC; Department of Surgery, Mayo Clinic Rochester, Rochester, Minnesota., Ellis ED; Medical Oncology, Swedish Cancer Institute, Seattle, Washington., Elias AD; Department of Medicine, University of Colorado, Denver., Lu J; Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles., Lang JE; Surgery, Keck School of Medicine, University of Southern California, Los Angeles., Han HS; Medical Oncology, Moffitt Cancer Center, Tampa, Florida., Clark AS; Perelman School of Medicine, University of Pennsylvania, Philadelphia., Nanda R; Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois., Northfelt DW; Medical Oncology, Mayo Clinic Scottsdale, Scottsdale, Arizona., Khan QJ; Medical Oncology, University of Kansas Medical Center, Lawrence., Viscusi RK; Hematology/Oncology, University of Arizona, Tucson., Euhus DM; Department of Surgery, Johns Hopkins Medicine, Baltimore, Maryland., Edmiston KK; Inova Schar Cancer Institute, Fairfax, Virginia., Chui SY; Genentech, South San Francisco, California., Kemmer K; Knight Cancer Institute, Oregon Health & Science University, Portland., Park JW; Division of Hematology and Oncology, University of California, San Francisco., Liu MC; Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota., Olopade O; Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois., Leyland-Jones B; Avera Cancer Institute, Sioux Falls, South Dakota., Tripathy D; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Moulder SL; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Rugo HS; Division of Hematology and Oncology, University of California, San Francisco., Schwab R; Medical Oncology, University of California, San Diego., Lo S; Medical Oncology, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois., Helsten T; Medical Oncology, University of California, San Diego., Beckwith H; Masonic Cancer Center, University of Minnesota, Minneapolis., Haugen P; National Breast Cancer Coalition, Washington, DC., Hylton NM; Department of Radiology and Biomedical Imaging, University of California, San Francisco., Van't Veer LJ; Department of Laboratory Medicine, University of California, San Francisco., Perlmutter J; Gemini Group, Ann Arbor, Michigan., Melisko ME; Division of Hematology and Oncology, University of California, San Francisco., Wilson A; Quantum Leap Healthcare Collaborative, San Francisco, California., Peterson G; Department of Surgery, University of California, San Francisco., Asare AL; Quantum Leap Healthcare Collaborative, San Francisco, California., Buxton MB; Berry Consultants, LLC, Austin, Texas., Paoloni M; Berry Consultants, LLC, Austin, Texas., Clennell JL; Berry Consultants, LLC, Austin, Texas., Hirst GL; Department of Surgery, University of California, San Francisco., Singhrao R; Department of Surgery, University of California, San Francisco., Steeg K; Department of Surgery, University of California, San Francisco., Matthews JB; Department of Surgery, University of California, San Francisco., Asare SM; Quantum Leap Healthcare Collaborative, San Francisco, California., Sanil A; Berry Consultants, LLC, Austin, Texas., Berry SM; Berry Consultants, LLC, Austin, Texas., Esserman LJ; Department of Surgery, University of California, San Francisco., Berry DA; Berry Consultants, LLC, Austin, Texas.

مؤلفون مشاركون: I-SPY2 Trial Consortium

المصدر: JAMA oncology [JAMA Oncol] 2020 Sep 01; Vol. 6 (9), pp. 1355-1362.

نوع المنشور: Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Breast Neoplasms/*drug therapy , Neoadjuvant Therapy/*adverse effects , Neoplasm Recurrence, Local/*drug therapy, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Bridged-Ring Compounds/administration & dosage ; Bridged-Ring Compounds/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Progression-Free Survival ; Proportional Hazards Models ; Receptor, ErbB-2/genetics ; Taxoids/administration & dosage ; Taxoids/adverse effects ; Trastuzumab/administration & dosage ; Trastuzumab/adverse effects ; Treatment Outcome